Background: To address the increasing age of pertussis cases, Yukon replaced the Grade 9 tetanus/diphtheria/inactivated polio booster with diphtheria/tetanus/acellular pertussis (dTap) and implemented a dTap catch-up program for Grade 12 students. The program began in June 2004, making Yukon one of the first Canadian jurisdictions to introduce dTap within five years of a tetanus booster. We implemented enhanced surveillance to monitor adverse events following immunization (AEFI) to determine whether students receiving dTap > or =3 to <5 years after their last tetanus booster were at increased risk of severe AEFI.
Methods: Students completed a self-administered AEFI questionnaire one week post-dTap vaccination. Public health professionals contacted students reporting severe AEFI. Health care providers were requested to report AEFI. Symptom rate, severity and duration were compared between students receiving dTap > or =3 to <5 years after their last tetanus booster and those receiving it >5 years later.
Results: The > or =3 to <5 years group was more likely than the > or =5 years group to report pain at the injection site (70.6% vs. 61.5%, p=0.038) and less likely to report injection site redness (10.0% vs. 17.3%, p=0.022), injection site swelling (8.9% vs. 16.4%, p=0.013), decreased energy (10.0% vs. 17.1%, p=0.023), body aches (2.2% vs. 7.2%, p=0.014) and sore joints (3.3% vs. 10.1%, p=0.004). Severe AEFI did not differ between the groups (3.3% vs. 5.6%, p=0.232). Health care professionals reported no AEFI.
Conclusions: Results suggest no increased risk of severe AEFI among students receiving dTap > or =3 to <5 years after their last tetanus booster.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976202 | PMC |
http://dx.doi.org/10.1007/BF03405229 | DOI Listing |
Dermatol Ther (Heidelb)
January 2025
Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", "Sapienza" University of Rome, Polo Pontino, 04100, Latina, Italy.
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and a relapsing course, affecting approximately 25% of children and 4-7% of adults. This study evaluated the efficacy, safety, and quality-of-life impact of tralokinumab, a humanized monoclonal antibody targeting interleukin-13 (IL-13), in treating moderate-to-severe AD in a real-world setting, with a focus on different AD phenotypes.
Methods: An observational cohort of 30 adults treated with tralokinumab for ≥ 16 weeks was analyzed.
Pharmaceutics
January 2025
Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, DK-5230 Odense, Denmark.
: The proton-coupled amino acid transporter (PAT1) is an intestinal absorptive solute carrier responsible for the oral bioavailability of some GABA-mimetic drug substances such as vigabatrin and gaboxadol. In the present work, we investigate if non-steroidal anti-inflammatory drug substances (NSAIDs) interact with substrate transport via human (h)PAT1. : The transport of substrates via hPAT1 was investigated in Caco-2 cells using radiolabeled substrate uptake and in oocytes injected with , measuring induced currents using the two-electrode voltage clamp technique.
View Article and Find Full Text PDFPathogens
January 2025
Biomedical Sciences Laboratory (CBMU), School of Medicine, Universidad de Los Andes, Bogotá D.C 111711, Colombia.
, the etiological agent of Chagas disease, is a parasite known for its diverse genotypic variants, or Discrete Typing Units (DTUs), which have been associated with varying degrees of tissue involvement. However, aspects such as parasite attachment remain unclear. It has been suggested that the TcI genotype is associated with cardiac infection, the most common involved site in chronic human infection, while TcII is associated with digestive tract involvement.
View Article and Find Full Text PDFMolecules
January 2025
Escuela Profesional de Farmacía y Bioquímica, Universidad Católica de Santa María, Urb. San José s/n, Umacollo, Arequipa 04000, Peru.
Epilepsy is a chronic neurological disorder that affects nearly 50 million people worldwide. Experimental evidence suggests that epileptic neurons are linked to the endocannabinoid system and that inhibition of the FAAH enzyme could have neuroprotective effects by increasing the levels of endogenous endocannabinoid anandamide. In this context, the use of macamides as therapeutic agents in neurological diseases has increased in recent years.
View Article and Find Full Text PDFLife (Basel)
December 2024
Department of Neurosciences, Institute of Human Anatomy, University of Padova, 35121 Padova, Italy.
The evolution of regional anesthesia techniques has markedly influenced the management of postoperative pain, particularly in thoracic surgery. As part of a multimodal analgesic approach, fascial plane blocks have gained prominence due to their efficacy in providing targeted analgesia with minimal systemic side effects. Among these, the superficial intercostal plane (SPIP) block and deep parasternal intercostal plane (DPIP) block are of notable interest.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!